Skip to main content

Medikamente zur Behandlung von Schlafstörungen

  • Chapter
Kompendium der Psychiatrischen Pharmakotherapie

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Medikamente gegen Schlafstörungen beschrieben. Diese werden entsprechend den DSM-5-Kriterien neu geordnet. Die Strukturen innerhalb der einzelnen Diagnosen sind geblieben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Allen RP, Picchietti DL, Auerbach M et al (2018) International Restless Legs Syndrome Study Group (IRLSSG). Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med 41: 27–44

    Google Scholar 

  • Dresler M, Spoormaker VI, Beitinger P et al (2014) Neuroscience-driven discovery and development of sleep therapeutics. Pharmacol Ther 141: 300–334

    Article  CAS  Google Scholar 

  • Garcia-Borreguero D, Cano-Pumarega I (2017) New concepts in the management of restless legs syndrome. BMJ 356: j104

    Google Scholar 

  • Iftikhar IH, Alghothani L, Trotti LM (2017) Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis. Eur J Neurol 24(12): 1446–1456

    Article  CAS  Google Scholar 

  • Keks NA, Hope J, Keogh S (2017) Suvorexant: scientifically interesting, utility uncertain. Australasian Psychiatry 25: 622–624

    Article  Google Scholar 

  • Mayer G (2014) Narkolepsie. Nervenarzt 85: 26–34

    Article  CAS  Google Scholar 

  • Moore TJ, Glemullen J, Mattison DR (2014) Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 174(12): 1930–1933

    Article  Google Scholar 

  • Muehlan C, Heuberger J, Juif PE et al (2018) Accelerated development of the dual orexin receptor antagonist ACT-541468: integration of a microtracer in a first-in-human study. Clin Pharmacol Ther. doi:10.1002/cpt.1046 [Epub ahead of print]

    Article  CAS  Google Scholar 

  • Nissen C, Frase L, Hajak G, Wetter TC (2014) Hypnotika – Stand der Forschung. Nervenarzt 85: 67–76

    Article  Google Scholar 

  • Pollmächer T, Wetter TC, Happe S et al (2014) Schlafmedizinische Differenzialdiagnostik in Psychiatrie und Psychotherapie. Nervenarzt 85: 57–66

    Article  Google Scholar 

  • Riemann D, Baglioni C, Feige B, Spiegelhalder K (2014) Insomnien – Stand der Forschung. Nervenarzt 85: 43–49

    Article  Google Scholar 

  • Riemann D, Baglioni C, Basetti C et al (2017a) European guideline for the diagnosis and treatment of insomnia. J Sleep Res 26: 675–600

    Google Scholar 

  • Riemann D, Baum E, Cohrs S et al (2017b) S3-Leitlinie Nicht erholsamer Schlaf/Schlafstörungen. Kapitel „Isomnie bei Erwachsenen“. Somnologie 21: 2–44

    Article  Google Scholar 

  • Saper CB, Fuller PM (2017) Wake-sleep circuitry: an overview. Curr Opin Neurobiol 44: 186–192

    Article  CAS  Google Scholar 

  • Silber MH, Becker PM, Buchfuhrer MJ et al; Scientific and Medical Advisory Board, Restless Legs Syndrome Foundation (2018) The appropriate use of opioids in the treatment of refractory restless legs syndrome. Mayo Clin Proc 93(1): 59–67

    Google Scholar 

  • Steiger A, Pawlowski M, Kimura M (2015) Sleep electroencephalography as a biomarker in depression. ChronoPhysiol Ther 5: 15–25

    Google Scholar 

  • Trenkwalder C, Benes H, Grote L et al, for the RELOXYN Study Group (2013) Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol 12: 1141–1150

    Google Scholar 

  • Trenkwalder C, Winkelmann J, Inoue Y, Paulus W (2015) Restless legs syndrome – current therapies and management of augmentation. Nat Rev Neurol 11(8): 434–445

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to A. Steiger , F. Weber or O. Benkert .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag GmbH Deutschland

About this chapter

Cite this chapter

Steiger, A., Weber, F., Benkert, O. (2019). Medikamente zur Behandlung von Schlafstörungen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57334-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-57334-1_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-57333-4

  • Online ISBN: 978-3-662-57334-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics